Hexamethonium compounds are a class of quaternary ammonium compounds widely recognized for their ability to block nicotinic acetylcholine receptors (nAChRs). These receptor antagonists, derived from the parent compound hexamethonium iodide, are utilized in various fields including pharmacology and basic research. In pharmacological studies, hexamethonium compounds serve as valuable tools to investigate the functions of nAChRs by preventing the binding of acetylcholine or other agonists, thus modulating neurotransmission pathways. They have been particularly useful in understanding the roles of these receptors in neuronal communication and synaptic plasticity. In practical applications, these compounds can be used in experimental setups to explore the effects of nicotinic receptor blockade on various physiological processes such as muscle relaxation, cardiovascular responses, and respiratory control. Due to their reversible nature at therapeutic concentrations, they offer a convenient means for temporary disruption of cholinergic activity without causing irreversible damage. Moreover, hexamethonium compounds have potential clinical applications, particularly in treating conditions related to excessive acetylcholine release or sensitivity to acetylcholine, such as certain types of hypertension and some cases of glaucoma. The study and application of these compounds continue to contribute significantly to our understanding of the complex mechanisms involved in cholinergic signaling.